Format

Send to

Choose Destination
See comment in PubMed Commons below
Mediterr J Hematol Infect Dis. 2012;4(1):e2012035. doi: 10.4084/MJHID.2012.035. Epub 2012 May 7.

Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis.

Author information

1
Hematology, "Sapienza" University of Rome. Via Benevento 6, 00161 Rome (Italy).

Abstract

INTRODUCTION:

Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).

METHODS:

We used Bortezomib without corticosteroids, to avoid the risk of lung infection reactivations due to patient's Pseudomonas aeruginosa colonization, in a MM patient with Cystic Fibrosis. Four 21-day cycles of Bortezomib were administrated at 1.3 mg/m(2) on days 1,4,8 and 11 with a 10 day rest period. Treatment response and toxicity were evaluated.

RESULTS:

After four cycles of therapy the patient achieved a very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.

CONCLUSIONS:

Bortezomib can be successfully utilized for the management of this difficult disease situation.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Catholic University in Rome, Institute of Hematology Icon for PubMed Central
    Loading ...
    Support Center